All activities in the Netherlands have been terminated as of June 20th 2024
enose video placeholder

Clarity is a breath away

aeoNose exhaled-breath analysis

Better diagnostics are just a breath away.

The eNose company aims to utilize the aeoNose, a portable breath analyzer, to overcome any obstacle that has thusfar prevented early detection of pathologies such as lung- and colon cancer. Our ultimate goal is to save lives and reduce the need for expensive and invasive tests and treatments.

More about The eNose Company
  • A test only takes 15 minutes
  • Ease of use

Detecting diseases through exhaled breath

Detecting lung cancer using the aeoNose

The air we exhale reflects our health. Components that are released from our body through exhaled breath (Volatile Organic Compounds or VOC’s) are perfectly suited to diagnose a variety of pathologies in humans. A disease can alter the specific composition of components found in exhaled breath. Years of careful development and training of the aeoNose using ‘breath prints’ now allows us to identify, classify and predict lung cancer in humans.

STATUS OF VALIDATION PROCESS ON LUNG CANCER DETECTION

In 2022, The eNose Company has finalized a ‘multi-center validation study’, which evaluates the aeoNose for the specific application of lung cancer detection. This clinical study was conducted by Dr Sharina Kort MD, and prospective pulmonologist at Medisch Spectrum Twente, Enschede, the Netherlands. Supervisors were Prof Job van der Palen, clinical epidemiologist at Medisch Spectrum Twente, Enschede, the Netherlands and Prof Michel van de Heuvel, pulmonologist at Radboudumc, Nijmegen, the Netherlands. Additionally, several major hospitals in the Netherlands participated in the study as well as the University hospital in Basel, Switzerland. Study results have been accepted for publication in ‘Chest’, hence suggesting the aeoNose most likely will be available for general use as a diagnostic tool for lung cancer by the end of 2022.

Currently, we are validating the aeoNose in the following hospitals

Publications

Detecting colorectal cancer using the aeoNose

The air we exhale reflects our health. Components that are released from our body through exhaled breath (Volatile Organic Compounds or VOC’s) are perfectly suited to diagnose a variety of pathologies in humans. A disease can alter the specific composition of components found in exhaled breath. Years of careful development and training of the aeoNose using ‘breath prints’ now allows us to identify, classify and predict lung cancer in humans.

STATUS OF THE VALIDATION PROCESS ON COLORECTAL CANCER DETECTION

Currently, the eNose Company is finishing up a ‘multi-center validation study’, which evaluates the aeoNose for the specific application of colorectal cancer detection. This clinical study is conducted by Ms. Milou van Riswijk, PhD student and prospective gastro-enterologist. Supervisor is Prof Peter Siersema, gastro-enterologist at Radboudumc, Nijmegen, the Netherlands. Several major hospitals in the Netherlands are participating in the study including Erasmus Medical Center, Rotterdam, the Netherlands. Study results are expected to be ready by the end of 2022 / beginning of 2023, hence suggesting the aeoNose most likely will be available for general use as a diagnostic tool for colorectal cancer by 2023.

Currently, we are validating the aeoNose in the following hospitals

Publications

COVID-19 detection using the aeoNose

The air we exhale reflects our health. Components that are released from our body through exhaled breath (Volatile Organic Compounds or VOC’s) are perfectly suited to diagnose a variety of pathologies in humans. A disease can alter the specific composition of components found in exhaled breath. Years of careful development and training of the aeoNose using ‘breath prints’ now allows us to identify, classify and predict lung cancer in humans.

STATUS OF THE VALIDATION PROCESS ON COVID-19 DETECTION

In close collaboration with ten hospitals in the Netherlands, the eNose Company is involved in a multi-center validation study on detecting COVID-19 using the aeoNose. Our goal is to develop a quick and accurate diagnostic test for healthcare workers. In addition we aim to demonstrate potential to apply the aeoNose as part of an early warning system by tracing and identifying future disease outbreaks.

Currently, we are validating the aeoNose in the following hospitals

Publications

FAQ

All exhaled-breath tests are being processed in a way that preserves anonymity by encryption. Actual classifications are visible in the electronic patient file only, and therefore not accessible by The eNose Company.

Results are stored in the electronic patient file and are only available to the patient and his/her healthcare professional.

Anonymized, numerical records of all screenings are encrypted and successively stored in an international BreathPrint™ database. Newly added breathprints contribute to improved, more accurate and smarter classification algorithms. In this way, this valuable source of information on exhaled-breath analysis of detectable diseases will be available to healthcare professionals around the globe.

Currently, a breath test for general practitioners is not available yet. However, development of such a test for GPs will start soon for a number of specific indications. At the moment, any trials for a self-test have not been planned.

In case the patient shows symptoms, the general practitioner or physician should consider performing the test, pending compatibility between symptoms and approved applications of the aeoNose.

The risk of cross-contamination is negligible. The following measures are in place to ensure this:

  • For each test, a new disposable mouthpiece is used,
  • For each mouthpiece, a so-called HEPA-filter is mounted, which filters out bacteria and viruses, thereby preventing them from entering the aeoNose device.
  • The patient inhales and exhales through the (new, disposable) mouthpiece, not directly through the aeoNose. The AeoNose has been approved by departments for infection prevention in several Dutch hospitals, including in the case of Covid-19.

News

PhD-defense Michiel Bannier

On June 22, 2023, Michiel Bannier, paediatric pulmonolgist at University Hospital Maastricht, the Netherlands, successfully defended his PhD-thesis.

Keynote at InterSystems Global Summit 2023

Prof Job van der Palen discussing the prospects of disease screening using an electronic nose.

PhD defense Yonne Peters (‘Cum laude’)

On May 11, 2023, Yonne Peters MD successfully defended her PhD-thesis ‘Early Detection of Esophageal Adenomacarcinoma and its Precursor Barrett’s Esophagus’ at Radboud University Nijmegen, the Netherlands.

The eNose Company will be present at HIMSS in Chicago, April 17-21, 2023

During the Healthcare Information and Management Systems Society (HIMSS) Global Health Conference & Exhibition in Chicago, we will demonstrate the lung cancer application of the aeoNose using the IRIS4Health Intersystems platform for HIS-communication. You can find us at the Intersystems Booth#942 South Building.

PhD-defense Rens van de Goor

On March 3rd, Rens van de Goor, otolaryngologist at Bernhoven hospital, Uden, the Netherlands, successfully defended his PhD-thesis ‘Non-invasive diagnostic of head and neck cancer: feasibility of a portable electronic nose’.

Detecting lung cancer with electronic nose

Is it possible to detect lung cancer by smelling the air that someone exhales? Sharina Kort, lung specialist in training at MST, recently earned a PhD from the University of Twente (TechMed Centre) based on her research into that topic.

Results of study presented at ERS Barcelona

Sharina Kort MD, PhD presented the results of the study ‘Diagnosing non-small cell lung cancer by exhaled breath profiling using an electronic nose: A multicentre validation study’ on the ERS congress 2022 in Barcelona. Using the aeoNose, lung cancer patients could non-invasively be distinguished from non-lung cancer participants in a multinational validation setting. A paper on this study has recently been accepted by ‘Chest’.
Aeonose breath analysis on TB screening South Africa

Aeonose breath analysis on TB screening South Africa

This year, the Union World Conference on Lung Health was held in Hyderabad, India. At the TBScience pre-conference, an official event entirely devoted to basic and translational tuberculosis (TB) research, study results were presented on the Aeonose exhaled-breath tests in Cape Town.
Guts_eNose

Just published in ‘Gut’, results from a pilot study on Barrett’s oesophagus using the Aeonose

This year, the Union World Conference on Lung Health was held in Hyderabad, India. At the TBScience pre-conference, an official event entirely devoted to basic and translational tuberculosis (TB) research, study results were presented on the Aeonose exhaled-breath tests in Cape Town.
eNose apt

Multicenter study Colon rectal cancer and advanced adenomas

Timely detection of oesophageal adenocarcinoma (OAC) and even more so its precursor Barrett’s oesophagus (BO) could contribute to decrease OAC incidence and mortality. An accurate, minimally-invasive screening method for BO for widespread use is currently not available. In a proof-of-principle study in 402 patients, we developed and cross-validated a BO prediction model using volatile organic compounds (VOCs) analysis with an electronic nose device. This electronic nose was able to distinguish between patients with and without BO with good diagnostic accuracy (sensitivity 91% specificity 74%) and seemed to be independent of proton pump inhibitor use, the presence of hiatal hernia, and reflux. This technique may enable an efficient, well-tolerated, and sensitive and specific screening method to select high-risk individuals to undergo upper endoscopy.

Click below to download the aeoNose user manual

White papers are available free of charge, covering use of the aeoNose, data analysis, background technology, and cost effectiveness.

© The eNose Company